Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Total Current Liabilities: 2017-2025

Historic Total Current Liabilities for Arcus Biosciences (RCUS) over the last 8 years, with Sep 2025 value amounting to $235.0 million.

  • Arcus Biosciences' Total Current Liabilities rose 9.30% to $235.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $235.0 million, marking a year-over-year increase of 9.30%. This contributed to the annual value of $226.0 million for FY2024, which is 22.83% up from last year.
  • As of Q3 2025, Arcus Biosciences' Total Current Liabilities stood at $235.0 million, which was up 11.90% from $210.0 million recorded in Q2 2025.
  • Arcus Biosciences' Total Current Liabilities' 5-year high stood at $235.0 million during Q3 2025, with a 5-year trough of $130.4 million in Q2 2021.
  • In the last 3 years, Arcus Biosciences' Total Current Liabilities had a median value of $200.0 million in 2023 and averaged $202.2 million.
  • Data for Arcus Biosciences' Total Current Liabilities shows a peak YoY increase of 528.71% (in 2021) and a maximum YoY decrease of 12.28% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Arcus Biosciences' Total Current Liabilities stood at $166.0 million in 2021, then increased by 16.27% to $193.0 million in 2022, then decreased by 4.66% to $184.0 million in 2023, then climbed by 22.83% to $226.0 million in 2024, then grew by 9.30% to $235.0 million in 2025.
  • Its last three reported values are $235.0 million in Q3 2025, $210.0 million for Q2 2025, and $192.0 million during Q1 2025.